Showing results (41-50 of 83) with videos related to
Sort By:
Pageof 9
Stem Cells (Dayton, Ohio)|June 23, 2009
Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogensJohn J P Kelly, Owen Stechishin, Andrew Chojnacki, et al.The Lancet. Oncology|December 18, 2007
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3Thierry Gorlia, Martin J van den Bent, Monika E Hegi, et al.Neuro-Oncology|December 25, 2013
Lactate dehydrogenase A silencing in IDH mutant gliomasCharles Chesnelong, Myriam M Chaumeil, Michael D Blough, et al.Neuro-Oncology|December 15, 2011
An in vivo patient-derived model of endogenous IDH1-mutant gliomaH Artee Luchman, Owen D Stechishin, N Ha Dang, et al.Cancer Cell|March 18, 2022
Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneityVéronique G LeBlanc, Diane L Trinh, Shaghayegh Aslanpour, et al.Cancer Research|June 6, 2015
IDH1 Mutation Induces Reprogramming of Pyruvate MetabolismJose L Izquierdo-Garcia, Pavithra Viswanath, Pia Eriksson, et al.Neuro-Oncology|December 7, 2013
A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettesTara Spence, Christian Perotti, Patrick Sin-Chan, et al.Biomaterials|May 18, 2020
Development of a peptide-based delivery platform for targeting malignant brain tumorsJennifer J Rahn, Xueqing Lun, Selina K Jorch, et al.Annals of Neurology|June 22, 2012
DNA hypermethylation and 1p Loss silence NHE-1 in oligodendrogliomaMichael D Blough, Mohammad Al-Najjar, Charles Chesnelong, et al.Journal of Neuro-Oncology|July 8, 2020
Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patientsSeth A Climans, Alba A Brandes, J Gregory Cairncross, et al.Pageof 9